Kura Oncology Provides Update on Phase Ib Study of KO-539 in Acute Myeloid Leukemia

Kura Oncology, Inc. announced that the US FDA has placed the KOMET-001 Phase Ib study of KO-539 in patients with relapsed or refractory acute myeloid leukemia on a partial clinical hold following the company’s recent report of a Grade 5 serious adverse event (patient death) potentially associated with differentiation syndrome.